Income statement
USD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Operating Income | 0 | -18M | -30M | -10M | -7M |
| EBITDA | 0 | -17M | -29M | -10M | -6M |
| Net Income | -30M | -22M | -29M | -9M | -7M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$2.59
+2.78% today
1Y Change
+15.28%
Window
Jun 26, 2025 → Jun 23, 2026
Coverage: 248 bars · Jun 26, 2025 → Jun 23, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
TuHURA Biosciences, Inc. (HURA) is a Healthcare stock with a market cap of $140.00M and listed on NASDAQ. The stock last traded around $2.59 and up 15.3% across the available one-year price window (Jun 26, 2025 → Jun 23, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +48.1%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +48.1%, free cash flow -87.4% with operating margin 0.0% and ROIC -147.0%. Stock Foundry combines HURA price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Edge
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
HURA
—
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
HURA Max Drawdown
-86.46%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for HURA and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$7.0M
+25.1% YoY
Free Cash Flow
-$6.6M
+13.0% YoY
Revenue Growth
+0.0%
EPS Growth
+48.1%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Operating Income | 0 | -18M | -30M | -10M | -7M |
| EBITDA | 0 | -17M | -29M | -10M | -6M |
| Net Income | -30M | -22M | -29M | -9M | -7M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 4M | 13M | 4M | 14M | 6M |
| Total Assets | 27M | 20M | 4M | 15M | 6M |
| Total Liabilities | 6M | 5M | 6M | 3M | 7M |
| Shareholder Equity | 21M | 15M | -2M | 12M | -748K |
| Total Debt | 503K | 203K | 2M | 138K | 644K |
| Net Debt | -3M | -12M | -1M | -14M | -5M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
7M
+12.6% YoY
Capital Expenditures
3K
+98.6% YoY
Free Cash Flow
7M
+13.0% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-179.4%
Debt / Equity
0.02x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.